<DOC>
	<DOCNO>NCT00005973</DOCNO>
	<brief_summary>Phase I trial study effectiveness BMS-214662 treating patient solid tumor . Drugs use chemotherapy use different way stop tumor cell divide stop growing die</brief_summary>
	<brief_title>BMS-214662 Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose BMS-214662 patient solid tumor . II . Evaluate intermediate biological endpoint surrogates effectiveness drug patient . III . Determine nature dose limit toxicity drug patient population . IV . Determine recommend phase II regimen drug patient . V. Establish pharmacologic pharmacokinetic profile drug patient . OUTLINE : This dose escalation study . Patients receive BMS-214662 IV 1 hour day 1 , 8 , 15 , 22 . Treatment repeat every 6 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos BMS-214662 maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose limit toxicity . Patients follow every 3 month least 24 month .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Diagnosis malignant solid tumor standard curative therapy exist Performance status Karnofsky 70100 % At least 6 month WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10.0 g/dL Bilirubin great 2.0 mg/dL AST great 2 time upper limit normal Albumin least 3.0 g/dL Creatinine great 1.5 mg/dL No uncontrolled heart disease No history clinically significant cardiac arrhythmia could exacerbate QT interval prolongation Corrected QT interval great 450 millisecond Must require total parenteral nutrition No manifestation malabsorption syndrome due prior surgery , gastrointestinal disease , unknown reason Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No sign symptom acute infection require systemic therapy No grade 3 4 neurotoxicity prior anticancer treatment neuropathy cause No confusion , disorientation , psychiatric illness may preclude study No 3 prior chemotherapy regimen At least 4 week since prior chemotherapy ( 6 week since prior nitrosoureas mitomycin ) recover No concurrent antineoplastic agent No concurrent hormonal anticancer therapy At least 4 week since prior radiotherapy No concurrent radiotherapy Prior drug know prolong QT interval allow safely discontinued time period equal 4 elimination halflives prior administer study drug No drug know prolong QT interval 24 hour study drug No concurrent therapy know CYP3A4 substrates No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>